PBS restriction changes for antihypertensive dual therapy fixed dose combinations

Page last updated: 1 April 2026

On 1 April 2026, PBS restrictions were changed to allow fixed dose combinations (FDCs) for dual therapy antihypertensives to be used as a first-line treatment for hypertension in line with international clinical guidelines. 30-day prescription items for antihypertensive dual therapy FDCs were changed to Unrestricted Benefit listings. 60‑day prescription items for antihypertensive dual therapy FDCs were changed to Restricted Benefit listings for patients whose condition is stable.

These changes implement recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) at its December 2024 meeting. Further information is available on the PBS restriction changes for antihypertensive dual therapy fixed dose combinations website.